Evidence map›Paper›PMID 35267033›Full record

ArticleJAMA network open2022

Trends in Cost Attributable to Kidney Transplantation Evaluation and Waiting List Management in the United States, 2012-2017.

Xingxing S Cheng, Jialin Han, Jennifer L Braggs-Gresham, Philip J Held, Stephan Busque, John P Roberts, Jane C Tan, John D Scandling, Glenn M Chertow, Avi Dor

Abstract read
In one paragraph

Article in JAMA network open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. What is Medicare Advantage and Why is it the Most Important Contemporary Policy Affecting Kidney Disease?American journal of kidney diseases : the official journal of the National Kidney Foundation · 2026
    Review
  5. Article
  6. Label-free viability assessment ofBiomedical optics express · 2026
    Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Evaluation for genetic disease in kidney transplant candidates: A practice resource.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2025
    Review
  12. Referral and Beyond: Restructuring the Kidney Transplant Process to Support Greater Access in the United States.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2024
    Article
  13. Article
  14. Review
  15. Article
  16. Point-of-care-ultrasound for the assessment of post-renal transplant recipients.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2024
    Article
  17. Article
  18. Review
  19. Article
  20. Cardiovascular Disease Assessment Prior to Kidney Transplantation.Methodist DeBakey cardiovascular journal · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xingxing S ChengDivision of Nephrology, Department of Medicine, Stanford University School of Medicine, Palo Alto, California.
Jialin HanDivision of Nephrology, Department of Medicine, Stanford University School of Medicine, Palo Alto, California.
Jennifer L Braggs-GreshamDivision of Nephrology, Department of Medicine, University of Michigan, Ann Arbor.
Philip J HeldDivision of Nephrology, Department of Medicine, Stanford University School of Medicine, Palo Alto, California.
Stephan BusqueDivision of Abdominal Transplantation, Department of Surgery, Stanford University School of Medicine, Palo Alto, California.
John P RobertsDivision of Transplant Surgery, Department of Surgery, University of California, San Francisco.
Jane C TanDivision of Nephrology, Department of Medicine, Stanford University School of Medicine, Palo Alto, California.
John D ScandlingDivision of Nephrology, Department of Medicine, Stanford University School of Medicine, Palo Alto, California.
Glenn M ChertowDivision of Nephrology, Department of Medicine, Stanford University School of Medicine, Palo Alto, California.
Avi DorGeorge Washington University, Milken Institute School of Public Health, Washington, DC.

Funding

Mentoring Patient-Oriented Clinical Investigators in NephrologyK24DK085446 · NIDDK · STANFORD UNIVERSITY · PI CHERTOW, GLENN MATTHEW · 2010 to 2022
$1.4M
Refining repeat screening for coronary artery disease in kidney transplant candidatesK23DK123410 · NIDDK · STANFORD UNIVERSITY · PI CHENG, XINGXING SHELLEY · 2020 to 2024
$826k
NIDDK NIH HHS K23 DK123410NIDDK NIH HHS K24 DK085446
6 · The paper itself

Abstract

Importance: While recent policy reforms aim to improve access to kidney transplantation for patients with end-stage kidney disease, the cost implications of kidney waiting list expansion are not well understood. The Organ Acquisition Cost Center (OACC) is the mechanism by which Medicare reimburses kidney transplantation programs, at cost, for costs attributable to kidney transplantation evaluation and waiting list management, but these costs have not been well described to date. Objectives: To describe temporal trends in mean OACC costs per kidney transplantation and to identify factors most associated with cost. Design, Setting, and Participants: This economic evaluation included all kidney transplantation waiting list candidates and recipients in the United States from 2012 to 2017. A population-based study of cost center reports was conducted using data from all Center of Medicare & Medicaid-certified transplantation hospitals. Data analysis was conducted from June to August 2021. Exposures: Year, local price index, transplantation and waiting list volume of transplantation program, and comorbidity burden. Main Outcomes and Measures: Mean OACC costs per kidney transplantation. Results: In 1335 hospital-years from 2012 through 2017, Medicare's share of OACC costs increased from $0.95 billion in 2012 to $1.32 billion in 2017 (3.7% of total Medicare End-Stage Renal Disease program expenditure). Median (IQR) OACC costs per transplantation increased from $81 000 ($66 000 to $103 000) in 2012 to $100 000 ($82 000 to $125 000) in 2017. Kidney organ procurement costs contributed to 36% of mean OACC costs per transplantation throughout the study period. During the study period, transplantation hospitals experienced increases in kidney waiting list volume, kidney waiting list active volume, kidney transplantation volume, and comorbidity burden. For a median-sized transplantation program, mean OACC costs per transplantation decreased with more transplants (-$3500 [95% CI, -$4300 to -$2700] per 10 transplants; P < .001) and increased with year ($4400 [95% CI, $3500 to $5300] per year; P < .001), local price index ($1900 [95% CI, $200 to $3700] per 10-point increase; P = .03), patients listed active on the waiting list ($3100 [95% CI, $1700 to $4600] per 100 patients; P < .001), and patients on the waiting list with high comorbidities ($1500 [9% CI, $600 to $2500] per 1% increase in proportion of waitlisted patients with the highest comorbidity score; P = .002). Conclusions and Relevance: In this study, OACC costs increased at 4% per year from 2012 to 2017 and were not solely attributable to the cost of organ procurement. Expanding the waiting list will likely contribute to further increases in the mean OACC costs per transplantation and substantially increase Medicare liability.

Indexed as

Kidney Failure, ChronicKidney TransplantationTissue and Organ ProcurementAgedFemaleHumansMaleMedicareUnited StatesWaiting Lists

Identifiers

PMID35267033
PMCPMC8914579

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.